Compared with bariatric surgery, they are non-invasive with no recovery time and nothing close to the outcome
[DOI] [PMC free article] [PubMed] [Google Scholar] 130.Stupnisek M., Franjic S., Drmic D., Hrelec M., Kolenc D., Radic B., Bojic D., Vcev A., Seiwerth S., Sikiric P
It's which mechanism isolates the variable you're testing
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
As a synthetic fragment of human GH residues 176-191, it allows researchers to study the metabolic arm of GH signalling independently of IGF-1 pathway activation